Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa

Antiviral Therapy

Volumn 18, Issue 7, 2013, Pages 915-920

  Hoffmann, Christopher J ^a,b   Ledwaba, Johanna ^c   Li, Jin Fen ^d   Johnston, Victoria ^e   Hunt, Gillian ^c   Fielding, Katherine L ^e   Chaisson, Richard E ^a   Churchyard, Gavin J ^b,e,f   Grant, Alison D ^e   Johnson, Jeffrey A ^d   Charalambous, Salome ^b   Morris, Lynn ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AURUM INSTITUTE   (South Africa)

^c NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; STAVUDINE; TENOFOVIR DISOPROXIL; VIRUS RNA; ZIDOVUDINE;

ADULT; ALLELE; ANTIVIRAL RESISTANCE; ARTICLE; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; CONSENSUS SEQUENCE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 (STRAIN C); HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SOUTH AFRICA; TREATMENT FAILURE; VIRUS MUTATION;

ADENINE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; ORGANOPHOSPHONATES; REVERSE TRANSCRIPTASE INHIBITORS; SOUTH AFRICA; TREATMENT FAILURE; VIRAL LOAD;

EID: 84886093851     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2652     Document Type: Article

References (27)

1. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Geneva: WHO 2010.
2. Brenner BG, Oliveira M, Doualla-Bell F, et al. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 2006;20:F9-F13.
3. Wainberg MA, Zaharatos GJ, Brenner BG. Development of antiretroviral drug resistance. N Engl J Med 2011;365:637-646.
4. Invernizzi C F, Coutsinos D, Oliveira M, Moisi D, Brenner BG, Wainberg MA. Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C. J Infect Dis 2009;200:1202-1206.
5. Li JF, Lipscomb JT, Wei X, et al. Detection of low-level K65R variants in nucleoside reverse transcriptase inhibitornaive chronic and acute HIV-1 subtype C infections. J Infect Dis 2011;203:798-802.
6. Orrell C, Walensky RP, Losina E, Pitt J, Freedberg KA, Wood R. HIV type-1 clade C resistance genotypes in treatment-naive patients and after irst virological failure in a large community antiretroviral therapy programme. Antivir Ther 2009;14:523-531.
7. Hosseinipour MC, Van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing irst-line antiretroviral therapy. AIDS 2009;23:1127-1134.
8. Van Zyl GU, Van Der Merwe L, Claassen M, Zeier M, Preiser W. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa. J Med Virol 2011;83:1764-1769.
9. Pillay V, Pillay C, Kantor R, Venter F, Levin L, Morris L. HIV type 1 subtype c drug resistance among pediatric and adult South African patients failing antiretroviral therapy. AIDS Res Hum Retroviruses 2008;24:1449-1454.
10. Theys K, Vercauteren J, Snoeck J, et al. HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir. Antimicrob Agents Chemother 2013;57:1053-1056.
11. Sunpath H, Wu B, Gordon M, et al. High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing irst-line regimen. AIDS 2012;26:1679-1684.
12. Hamers RL, Sigaloff KC, Wensing AM, et al. Patterns of HIV-1 drug resistance after irst-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis 2012;54:1660-1669.
13. Charalambous S, Grant AD, Day JH, et al. Establishing a workplace antiretroviral therapy programme in South Africa. AIDS Care 2007;19:34-41.
14. Innes C, Hamilton R, Hoffmann CJ, et al. A novel HIV treatment model using private practitioners in South Africa. Sex Transm Infect 2012;88:136-140.
15. Pillay V, Ledwaba J, Hunt G, et al. Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir Ther 2008;13 Suppl 2:101-107.
16. Zhou Z, Wagar N, De Vos JR, et al. Optimization of a low cost and broadly sensitive genotyping assay for HIV-1 drug resistance surveillance and monitoring in resource-limited settings. PLoS ONE 2011;6:e28184.
17. Johnson VA, Calvez V, Gunthard HF, et al. 2011 Update of the drug resistance mutations in HIV-1. Top Antivir Med 2011;19:156-164.
18. Gallant JE, De Jesus E, Arribas JR, et al. Tenofovir D F, emtricitabine, and efavirenz vs zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006;354:251-260.
19. Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009;361:2230-2240.
20. Margot NA, Lu B, Cheng A, Miller MD. Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903. HIV Med 2006;7:442-450.
21. DART Virology Group and Trial Team. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 2006;20:1391-1399.
22. Gallant JE, Staszewski S, Pozniak AL, et al. Eficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004;292:191-201.
23. Margot NA, Isaacson E, McGowan I, Cheng AK, Schooley RT, Miller MD. Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. AIDS 2002;16:1227-1235.
24. Pozniak A. Tenofovir: what have over 1 million years of patient experience taught us? Int J Clin Pract 2008;62:1285-1293.
25. Kagan RM, Lee TS, Ross L, Lloyd RM, Jr., Lewinski MA, Potts SJ. Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase. Antiviral Res 2007;75:210-218.
26. Delaugerre C, Flandre P, Marcelin AG, et al. National survey of the prevalence and conditions of selection of HIV-1 reverse transcriptase K70E mutation. J Med Virol 2008;80:762-765.
27. Van Rompay KK, Johnson JA, Blackwood EJ, et al. Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection. Retrovirology 2007;4:25.